Search
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalFood and Drug Administration on August 1, 2017. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … Bimekizumab was also granted FDA approval on October 18, 2023.[L48551]
Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalDeveloped by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099]. … Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099
Synonyms: - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, TUlobetasol
go.drugbank.com/drugs/DB00596Approved[L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047] … [A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.
Coagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalHowever its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
go.drugbank.com/drugs/DB10061ApprovedInvestigationalfour drug substances contained in each dose of vaccine. … [A253277] Several serogroups of _N. meningitidis_ - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.
Aluminum sulfate
go.drugbank.com/drugs/DB11239ApprovedAl is found in materials used in the pharmaceutical industry, and in manufactured foodstuffs, cosmetics, and tap water. … Aluminum (Al) is ubiquitous and represents the third most common element in the Earth’s crust. It most commonly exists in a combined state with various other elements.
Products: Trim Men Styptic PencilSuccinic acid
go.drugbank.com/drugs/DB00139ApprovedInvestigationalNutraceutical(Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851) … A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters.
Abametapir
go.drugbank.com/drugs/DB11932Approved[A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … [A216178] Abemetapir is an inhibitor of these metalloproteinase enzymes, and the first topical pediculicide to take advantage of this novel target.
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalThe main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".